The FDA's Circulatory System Devices Panel recommended that the cardiac resynchronization therapy defibrillator (CRT--D), developed by Boston Scientific, be approved for use in patients with mild heart failure in the United States. If the device is approved by the FDA, nearly 4 million more Americans could be candidates for treatment with the CRT-D.
Read »- Anonymous
Navigation
User login
Visit the BiotechMashup Blog
Best upcoming scoops - Health
- New ways sleep-wake patterns are like clockwork
- Unsafe at any speed: Even for driving pros, distractions increase crash risk
- Fever during pregnancy more than doubles the risk of autism or developmental delay
- Scientists unravel role of fusion gene in prostate cancer
- Food fight or romantic dinner? Communication between couples is key to improving men's diets